Clinical Neuropharmacology最新文献_第7页

The Experiences and Unmet Supportive Care Needs of Partners of Men Diagnosed With Prostate Cancer: A Meta-aggregation Systematic Review. 前列腺癌患者伴侣的经历和未满足的支持性护理需求：元聚合系统综述》。

IF 1 4区医学

Clinical Neuropharmacology Pub Date : 2024-02-02 DOI: 10.1097/NCC.0000000000001172

Cara Roberts, Kellie Toohey, Catherine Paterson

{"title":"The Experiences and Unmet Supportive Care Needs of Partners of Men Diagnosed With Prostate Cancer: A Meta-aggregation Systematic Review.","authors":"Cara Roberts, Kellie Toohey, Catherine Paterson","doi":"10.1097/NCC.0000000000001172","DOIUrl":"10.1097/NCC.0000000000001172","url":null,"abstract":"Background: Partners of men diagnosed with prostate cancer face their own emotional struggles as they navigate additional caregiver responsibilities while concurrently adjusting to the diagnosis and coping with greater illness uncertainty for their loved one.Objective: This qualitative systematic review examined the unmet supportive care needs of partners affected by prostate cancer.Interventions/methods: A meta-aggregation was conducted. Four electronic databases were searched using key words. The methodology followed the Joanna Briggs Institute for qualitative evidence synthesis. The review process followed a registered priori review protocol and was reported using the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-analysis) guidelines. Data extraction and quality assessment were conducted in parallel.Results: Twenty-one publications were included. A total of 239 findings and 32 categories were synthesized into 7 domains of unmet needs as experienced by partners. The domains of needs expressed by the participants included interpersonal/intimacy, physical/daily living, healthcare service, family-related, psychological/emotional needs, and spiritual and social needs.Conclusions: There are gaps in clinical service support, despite routine clinical consultation with healthcare professionals. Partners may diminish their social networks to protect their husband at the cost to their own self-preservation and well-being.Implications for practice: Cancer organizations, policy makers, healthcare care professionals, and researchers are slowly making progress to acknowledge the unique support needs of partners affected by cancer. Healthcare professionals should encourage partners to be included in models of prehabilitation to access timely support to address informational, intimacy, spiritual, and daily living needs support.","PeriodicalId":10449,"journal":{"name":"Clinical Neuropharmacology","volume":" ","pages":""},"PeriodicalIF":1.0,"publicationDate":"2024-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10645191","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Effect of Levodopa on Heat Hypersensitivity and Complex Motor Parkinsonism. 左旋多巴对热敏感和复杂运动性帕金森症的影响

IF 1 4区医学

Clinical Neuropharmacology Pub Date : 2024-01-01 Epub Date: 2023-12-27 DOI: 10.1097/WNF.0000000000000580

Eric Noyes, Ali H Rajput, Sarah Bocking, Alex Rajput

{"title":"Effect of Levodopa on Heat Hypersensitivity and Complex Motor Parkinsonism.","authors":"Eric Noyes, Ali H Rajput, Sarah Bocking, Alex Rajput","doi":"10.1097/WNF.0000000000000580","DOIUrl":"10.1097/WNF.0000000000000580","url":null,"abstract":"Objectives: The aim of the study is to report a case with heat intolerance, complex motor fluctuations, and parkinsonism.Materials and methods: A male with onset of heat intolerance at the age of 46 years developed left upper limb tremor at the age of 58 years. He was diagnosed with Parkinson disease at the age of 62 years and presented to Movement Disorders Clinic Saskatchewan at the age of 65 years. He reported motor response fluctuations, including WO and dyskinesias. There was no history of dizziness on standing, bladder, or sexual dysfunction. We recorded an asymptomatic drop of orthostatic blood pressure. He reported loss of smell sensation for 5 years and REM behavior disorder characterized by talking in his sleep. He was assessed at the age of 65 years over the course of a day with 4 video recordings of his evolving findings and symptoms with his informed consent.Results: Initial assessment after levodopa was withheld more than 14 hours revealed him to be 'off' with severe dystonic neck flexion and with bradykinesia and rigidity in the limbs. He was anhidrotic, felt hot, and needed a wet towel over his neck. Over the course of 4 hours, he turns \"on\" with improvement in heat intolerance, neck hypertonicity, and parkinsonian findings and develops evolving dyskinetic movements before turning \"off\" again. His overall clinical picture was most consistent with multiple system atrophy.Conclusions: Heat intolerance can precede onset of motor symptoms of parkinsonism by several years and supports a diagnosis of multiple system atrophy. To our knowledge, this is the first documented case of improvement in heat intolerance with levodopa.","PeriodicalId":10449,"journal":{"name":"Clinical Neuropharmacology","volume":" ","pages":"29-32"},"PeriodicalIF":1.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139058190","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Involvement of Plasma Melatonin in Medication-Overuse Headache: A Cross-Sectional Study. 血浆褪黑激素与药物过量头痛的关系：一项横断面研究。

IF 1 4区医学

Clinical Neuropharmacology Pub Date : 2024-01-01 Epub Date: 2023-10-19 DOI: 10.1097/WNF.0000000000000573

Huimin Tao, Qi Wan, Mei Sun, Kefu Cai, Yan Song, Mingqing He, Jiabing Shen

{"title":"Involvement of Plasma Melatonin in Medication-Overuse Headache: A Cross-Sectional Study.","authors":"Huimin Tao, Qi Wan, Mei Sun, Kefu Cai, Yan Song, Mingqing He, Jiabing Shen","doi":"10.1097/WNF.0000000000000573","DOIUrl":"10.1097/WNF.0000000000000573","url":null,"abstract":"Objectives: Patients with medication-overuse headache (MOH) are often complicated with anxiety, depression, and sleep disorders and are associated with dependence behavior and substance abuse. Melatonin has physiological properties including analgesia, regulation of circadian rhythms, soporific, and antidepressant and affects drug preference and addiction. This study aimed to investigate the role of melatonin in MOH compared with episodic migraine (EM) and healthy controls and to verify the relationship between plasma melatonin levels and psychiatric symptoms.Methods: Thirty patients affected by MOH, 30 patients with EM, and 30 matched healthy controls were enrolled. All subjects completed a detailed headache questionnaire and scales including the Hospital Anxiety and Depression Scale (HADS), the Pittsburgh Sleep Quality Index, the Leeds Dependence Questionnaire. Melatonin levels in plasma samples were measured by enzyme immunoassay method.Results: The levels of plasma melatonin were significantly different among 3 groups of subjects (MOH, 7.74 [5.40-9.89]; EM, 9.79 [8.23-10.62]; Control, 10.16 [8.60-17.57]; H = 13.433; P = 0.001). Significantly lower levels of melatonin were found in MOH patients compared with healthy controls ( P = 0.001). The level of plasma melatonin inversely correlated with the scores of HADS-Anxiety ( r = -0.318, P = 0.002), HADS-Depression ( r = -0.368, P < 0.001), Pittsburgh Sleep Quality Index ( r = -0.303, P = 0.004), and Leeds Dependence Questionnaire ( r = -0.312, P = 0.003).Conclusions: This study innovatively detects the plasma melatonin levels in MOH patients and explores the association between melatonin levels and psychiatric symptoms. Melatonin may be potential complementary therapy in the treatment of MOH considering its comprehensive role in multiple aspects of MOH.","PeriodicalId":10449,"journal":{"name":"Clinical Neuropharmacology","volume":" ","pages":"12-16"},"PeriodicalIF":1.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49675060","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Efficacy and Safety of Rimegepant for Migraine Patients: A Meta-analysis of Randomized Controlled Studies. Rimegepant治疗偏头痛患者的疗效和安全性：随机对照研究的荟萃分析。

IF 1 4区医学

Clinical Neuropharmacology Pub Date : 2024-01-01 Epub Date: 2023-11-01 DOI: 10.1097/WNF.0000000000000576

Chao Yang, Yue Zhang

{"title":"Efficacy and Safety of Rimegepant for Migraine Patients: A Meta-analysis of Randomized Controlled Studies.","authors":"Chao Yang, Yue Zhang","doi":"10.1097/WNF.0000000000000576","DOIUrl":"10.1097/WNF.0000000000000576","url":null,"abstract":"Objectives: Rimegepant may have some potential in treating migraine, and this meta-analysis aims to study the efficacy and safety of rimegepant for migraine patients.Methods: We have searched several databases including PubMed, Embase, Web of Science, EBSCO, and Cochrane Library databases and selected the randomized controlled trials comparing the efficacy of rimegepant versus placebo for migraine patients. This meta-analysis was conducted using the random- or fixed-effect model based on the heterogeneity.Results: Three randomized controlled trials were included in this meta-analysis. Compared with placebo in migraine patients, rimegepant treatment was associated with substantially improved freedom from pain at 2 hours (odds ratio [OR], 2.10; 95% confidence interval [CI], 1.69-2.59; P < 0.00001), pain relief at 2 hours (OR, 1.93; 95% CI, 1.65 to 2.25; P < 0.00001), freedom from the most bothersome symptom at 2 hours (OR, 1.61; 95% CI, 1.35-1.91; P < 0.00001), ability to function normally at 2 hours (OR, 1.69; 95% CI, 1.42-2.01; P < 0.00001), sustained freedom from pain at 24 hours (OR, 2.88; 95% CI, 1.74-4.78; P < 0.0001), sustained pain relief at 24 hours (OR, 2.31; 95% CI, 1.96-2.72; P < 0.00001), and no rescue medication (OR, 2.42; 95% CI, 2.02-2.90; P < 0.00001) but showed no obvious impact on adverse events (OR, 1.27; 95% CI, 1.01-1.60; P = 0.04).Conclusions: Rimegepant may be effective and safe for the treatment of migraine patients.","PeriodicalId":10449,"journal":{"name":"Clinical Neuropharmacology","volume":" ","pages":"7-11"},"PeriodicalIF":1.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71421273","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A Case of Neuroleptic Malignant Syndrome in the Context of Lithium Toxicity and Aripiprazole Use. 锂毒性和阿立哌唑使用背景下的一例抗精神病药物恶性综合征。

IF 1 4区医学

Clinical Neuropharmacology Pub Date : 2024-01-01 Epub Date: 2023-10-23 DOI: 10.1097/WNF.0000000000000575

Autumn R Schultz, Sarina Singh, Carolyn E Linek-Rajapaksha, Heather R Goode, Adam J Fusick

{"title":"A Case of Neuroleptic Malignant Syndrome in the Context of Lithium Toxicity and Aripiprazole Use.","authors":"Autumn R Schultz, Sarina Singh, Carolyn E Linek-Rajapaksha, Heather R Goode, Adam J Fusick","doi":"10.1097/WNF.0000000000000575","DOIUrl":"10.1097/WNF.0000000000000575","url":null,"abstract":"Objective: Neuroleptic malignant syndrome (NMS) is a rare life-threatening condition that providers should be cognizant of when prescribing dopamine-receptor antagonists. Atypical antipsychotic agents were initially considered to have a lower risk of inducing the development of NMS compared with conventional antipsychotic. Considerable evidence, however, has suggested that atypical antipsychotics are associated with NMS, including the partial dopamine agonist, aripiprazole. There is growing evidence that other psychotropics, including lithium, cause this condition. Here, the authors present a case of a patient who developed NMS from lithium and aripiprazole and provide a literature review of reported NMS cases with either psychotropic.Method and results: The authors report the case of 60-year-old male patient who developed NMS over a hospital course during which both aripiprazole and lithium were prescribed. In addition, a literature review was performed and a summary of cases of NMS induced by either lithium and/or aripiprazole is provided.Conclusions: This case adds to the growing body of literature of aripiprazole and lithium-induced NMS. Only 2 other cases are reported where concomitant aripiprazole and lithium use lead to NMS. Interestingly, our patient did develop lithium toxicity during hospitalization, but the NMS diagnosis occurred after lithium toxicity resolved. This varies from the other 2 cases where NMS developed despite lithium levels always being therapeutic. Unfortunately, there are more questions than answers surrounding this rare complication involving these 2 psychotropics and clinical vigilance is warranted when using these psychotropics especially in cases where aripiprazole and lithium are used in combination.","PeriodicalId":10449,"journal":{"name":"Clinical Neuropharmacology","volume":" ","pages":"22-25"},"PeriodicalIF":1.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49689030","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Esketamine Augmentation in Treatment-Resistant Obsessive-Compulsive Disorder: A Retrospective Chart Review. 艾司西他敏增强治疗难治性强迫症：回顾病历

IF 1 4区医学

Clinical Neuropharmacology Pub Date : 2024-01-01 Epub Date: 2024-01-02 DOI: 10.1097/WNF.0000000000000578

Raíza Alves-Pereira, Mariana Fontes, Vivian Cordeiro, Igor D Bandeira, Daniela Faria-Guimarães, Samantha S Silva, Rodrigo P Mello, Gustavo C Leal, Aline S Sampaio, Lucas C Quarantini

{"title":"Esketamine Augmentation in Treatment-Resistant Obsessive-Compulsive Disorder: A Retrospective Chart Review.","authors":"Raíza Alves-Pereira, Mariana Fontes, Vivian Cordeiro, Igor D Bandeira, Daniela Faria-Guimarães, Samantha S Silva, Rodrigo P Mello, Gustavo C Leal, Aline S Sampaio, Lucas C Quarantini","doi":"10.1097/WNF.0000000000000578","DOIUrl":"10.1097/WNF.0000000000000578","url":null,"abstract":"Objective: Converging evidence supports the role of the glutamate, an excitatory amino acid neurotransmitter, in the pathophysiology of obsessive-compulsive disorder (OCD). Ketamine and esketamine, both noncompetitive N -methyl- d -aspartate antagonists, have emerged as a promising medication for this psychiatric disorder, given its possible efficacy with faster onset and good tolerability. The purpose of this retrospective chart review is to evaluate whether unbiased clinical documentation supports formal clinical trials of esketamine for an OCD indication.Methods: A retrospective chart review of patients with treatment-resistant OCD receiving a single dose of esketamine (0.5mg/kg) added to standard therapy was conducted. The Yale-Brown Obsessive-Compulsive Scale and the Montgomery-Åsberg Depression Rating Scale were used to evaluate OCD and depressive symptoms respectively at baseline, 24 hours, and 7 days after esketamine administration. Descriptive statistics were used to analyze the data.Results: Eight subjects were identified in this retrospective chart review: esketamine was administered subcutaneously in 7 and intravenously in 1. One week after infusion, 25% of the sample met criteria for treatment response and 50% for partial response. Major depressive disorder was a comorbid diagnosis in 75% of the sample and 2 of these subjects showed a positive antidepressant response.Conclusions: Our findings provide preliminary evidence that esketamine may reduce obsessive-compulsive symptoms in a subset of treatment-resistant OCD patients.","PeriodicalId":10449,"journal":{"name":"Clinical Neuropharmacology","volume":" ","pages":"17-21"},"PeriodicalIF":1.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139402158","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comparison of Lasmiditan 200 mg Versus 100 mg for Migraine Patients: A Meta-analysis of Randomized Controlled Studies. 偏头痛患者服用 Lasmiditan 200 毫克与 100 毫克的比较：随机对照研究的 Meta 分析。

IF 1 4区医学

Clinical Neuropharmacology Pub Date : 2024-01-01 Epub Date: 2023-12-18 DOI: 10.1097/WNF.0000000000000567

Chuan Zhong, Xuanqin Zhang, Guoyong Qin, Jixiang Wu, Yongpan Tian

{"title":"Comparison of Lasmiditan 200 mg Versus 100 mg for Migraine Patients: A Meta-analysis of Randomized Controlled Studies.","authors":"Chuan Zhong, Xuanqin Zhang, Guoyong Qin, Jixiang Wu, Yongpan Tian","doi":"10.1097/WNF.0000000000000567","DOIUrl":"10.1097/WNF.0000000000000567","url":null,"abstract":"Introduction: The ideal dose of lasmiditan for migraine is not clear. This meta-analysis aims to compare the efficacy of lasmiditan 200 mg versus 100 mg for migraine patients.Methods: We have searched several databases including PubMed, Embase, Web of Science, EBSCO, and Cochrane Library Databases and selected the randomized controlled trials comparing the efficacy of lasmiditan 200 mg versus 100 mg for migraine patients. This meta-analysis was conducted using the random-effect model.Results: Five randomized controlled trials were included in this meta-analysis. Compared with lasmiditan 100-mg group in migraine patients, lasmiditan 200-mg group was associated with substantially increased pain free at 2 hours (odds ratio [OR], 1.27; 95% confidence interval [CI], 1.12-1.44; P = 0.0002) and pain free at 24 hours (OR, 1.31; 95% CI, 1.08-1.60; P = 0.007) but demonstrated no obvious impact on pain relief at 2 hours (OR, 1.02; 95% CI, 0.91-1.16; P = 0.72) or MBS free at 2 hours (OR, 0.94; 95% CI, 0.77-1.14; P = 0.52). In addition, the incidence of adverse events was higher in lasmiditan 200-mg group than that in lasmiditan 100-mg group (OR, 1.29; 95% CI, 1.15-1.45; P < 0.0001).Conclusions: Lasmiditan 200 mg is better for the treatment of migraine patients than lasmiditan 100 mg.","PeriodicalId":10449,"journal":{"name":"Clinical Neuropharmacology","volume":" ","pages":"1-6"},"PeriodicalIF":1.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139058189","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Marked Decreased Tracer Binding in 123 I-FP-CIT SPECT Scans From Lisdexafetamine Dismesylate Interaction: A Case Report. Lisdexafetamine Dismesylate相互作用导致 123I-FP-CIT SPECT 扫描中示踪剂结合明显减少：病例报告

IF 0.8 4区医学

Clinical Neuropharmacology Pub Date : 2024-01-01 Epub Date: 2024-02-02 DOI: 10.1097/WNF.0000000000000579

Toji Miyagawa, Cynthia Vernon, Scott A Przybelski, Hoon-Ki Min, Julie A Fields, Kejal Kantarci, Val Lowe, Bradley F Boeve

{"title":"Marked Decreased Tracer Binding in 123 I-FP-CIT SPECT Scans From Lisdexafetamine Dismesylate Interaction: A Case Report.","authors":"Toji Miyagawa, Cynthia Vernon, Scott A Przybelski, Hoon-Ki Min, Julie A Fields, Kejal Kantarci, Val Lowe, Bradley F Boeve","doi":"10.1097/WNF.0000000000000579","DOIUrl":"10.1097/WNF.0000000000000579","url":null,"abstract":"Objectives: The objective of this case study is to raise awareness of potential 123 I-FP-CIT SPECT interference by lisdexafetamine dimesylate, a prodrug of d -amphetamine.Methods: A 69-year-old man with Rapid Eye Movement sleep behavior disorder and mild cognitive impairment had been treated with lisdexafetamine dimesylate for attention-deficit/hyperactivity disorder. The patient had annual or biennial 123 I-FP-CIT SPECT evaluations after their baseline visit at 69 years old. Nigrostriatal dopamine transporter uptake was semiquantitatively evaluated with 123 I-FP-CIT SPECT using DaTQUANT 2.0 software. Lisdexafetamine dimesylate was discontinued 3 months before the sixth-year visit (76 years old) by his primary care provider.Results: The patient had 4 123 I-FP-CIT SPECT scans with lisdexafetamine dimesylate and 2 scans after the discontinuation of lisdexafetamine dimesylate. The DaTQUANT z -scores of the putamen declined from -1.36 at the baseline visit to -3.02 at the fifth-year visit. After the discontinuation of lisdexafetamine dimesylate, DaTQUANT z -scores of the putamen increased to -0.63 at the sixth-year visit and remained in the normal range of -0.71 at the seventh-year visit.Conclusions: This case suggests that lisdexafetamine dimesylate may have a strong interference with 123 I-FP-CIT SPECT, decreasing the tracer binding to the dopamine transporter and presenting false positive results.","PeriodicalId":10449,"journal":{"name":"Clinical Neuropharmacology","volume":" ","pages":"26-28"},"PeriodicalIF":0.8,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10872469/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139402159","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

An Examination of the Relationship Between Exposure to Bisphenol A and Attention-Deficit/Hyperactivity Disorder in Children and Adolescents. 儿童和青少年双酚A暴露与注意缺陷/多动障碍关系的研究。

IF 1 4区医学

Clinical Neuropharmacology Pub Date : 2023-11-01 Epub Date: 2023-10-16 DOI: 10.1097/WNF.0000000000000574

Saliha Baykal, Ayşin Nalbantoğlu

{"title":"An Examination of the Relationship Between Exposure to Bisphenol A and Attention-Deficit/Hyperactivity Disorder in Children and Adolescents.","authors":"Saliha Baykal, Ayşin Nalbantoğlu","doi":"10.1097/WNF.0000000000000574","DOIUrl":"10.1097/WNF.0000000000000574","url":null,"abstract":"Objectives: Exposure to environmental toxic agents in the prenatal and/or postnatal periods may play in the acquired development of attention-deficit/hyperactivity disorder (ADHD) in groups with genetic risks. Bisphenol A (BPA) is a widely used industrial chemical with neurotoxic effects. This study examined the relationship between exposure to BPA and clinical ADHD.Methods: This cross-sectional, case-controlled clinical study compared 45 drug-naive children and adolescents with ADHD and 30 healthy controls in terms of serum BPA levels. Psychiatric comorbidities in the ADHD group were determined using the \"Schedule for Affective Disorders and Schizophrenia for school-aged children, lifetime version.\" The Child Behavior Checklist (CBCL) was also administered to all participants.Results: Serum BPA levels were significantly higher in the ADHD group than in the healthy control group. In addition, significant, weak positive correlation was found between BPA levels and CBCL attention and CBCL total problem scores.Conclusions: Our results show that BPA may be an environmental toxic agent with a potential role in the etiology of ADHD and particularly attention deficiency. Preventive interventions can be developed if this can be confirmed with longitudinal studies and repeated measurements.","PeriodicalId":10449,"journal":{"name":"Clinical Neuropharmacology","volume":"46 6","pages":"214-219"},"PeriodicalIF":1.0,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"92153007","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Neuroleptic Malignant Syndrome in Patients With Dementia: Experiences of A Single Memory Clinic. 痴呆患者的抗精神病药恶性综合征:单一记忆诊所的经验。

IF 1 4区医学

Clinical Neuropharmacology Pub Date : 2023-11-01 Epub Date: 2023-09-18 DOI: 10.1097/WNF.0000000000000570

Ahmet Turan Isik, Derya Kaya, Mehmet Selman Ontan, Feyza Mutlay, Esra Ates Bulut, Fatma Sena Dost, Neziha Erken, Ali Ekrem Aydin

{"title":"Neuroleptic Malignant Syndrome in Patients With Dementia: Experiences of A Single Memory Clinic.","authors":"Ahmet Turan Isik, Derya Kaya, Mehmet Selman Ontan, Feyza Mutlay, Esra Ates Bulut, Fatma Sena Dost, Neziha Erken, Ali Ekrem Aydin","doi":"10.1097/WNF.0000000000000570","DOIUrl":"10.1097/WNF.0000000000000570","url":null,"abstract":"Objectives: Neuroleptic malignant syndrome (NMS) is a life-threatening condition that occurs as an adverse reaction to antipsychotic and antiemetic agents or sudden withdrawal of dopaminergic medications. Given the metabolic and functional reserves and the comorbidities in older adults, NMS may show an atypical course.Methods: The medical records of patients with neurodegenerative diseases leading to dementia between 2013 and 2020 were reviewed for the diagnosis of NMS. Demographic and clinical characteristics of the patients were obtained from the records of laboratory parameters, management, and length of stay.Results: Fifteen older adults (19 episodes) diagnosed with NMS were included. The median age was 76 years, and 5 were female. Ten of 15 NMS patients were atypical. Most of them had an infection accompanying NMS. Neuroleptic malignant syndrome was caused by antidopaminergic agents (5 antipsychotics, 1 metoclopramide) in 6 episodes and discontinuation of a dopaminergic agent, l -DOPA, in 12 episodes. In 1 patient, it was associated with simultaneous use of domperidone and amantadine withdrawal. Rigidity in NMS due to l -DOPA discontinuation was higher than in those due to antipsychotic use ( P = 0.027). Two of our patients needed intensive care, and 1 died.Conclusions: This study highlights the high frequency of atypical NMS and the importance of early recognition of this potentially fatal syndrome, which can accompany neurodegenerative diseases and infections in older adults.","PeriodicalId":10449,"journal":{"name":"Clinical Neuropharmacology","volume":"46 6","pages":"209-213"},"PeriodicalIF":1.0,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"92153049","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0